Pub Date : 2019-05-29DOI: 10.23937/2572-3308.1510040
O. Mohamed, T. Osborne, J. Heslegrave, M. Krishna
{"title":"Anaphylaxis to Water Caltrop (Singoda Flour): A Case Report","authors":"O. Mohamed, T. Osborne, J. Heslegrave, M. Krishna","doi":"10.23937/2572-3308.1510040","DOIUrl":"https://doi.org/10.23937/2572-3308.1510040","url":null,"abstract":"","PeriodicalId":138186,"journal":{"name":"International Journal of Allergy Medications","volume":"202 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127584124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-04-03DOI: 10.23937/2572-3308.1510038
N. Germain, R. V. Wijk, S. Aballéa, L. Abetz-Webb, A. Domdey, M. Romano, M. Toumi
Background: Allergic rhinitis is a major chronic respiratory disease that affects between 10% and 30% of adults and up to 40% of children globally. The purpose of this study was to understand the impact of allergic rhinitis and subsequent GRAZAX® grass allergy immunotherapy (AIT) treatment on adults’ and adolescents’ quality of life. Methods: Clinicians treating allergic rhinitis in the Netherlands and Germany recruited adults and adolescents who had received at least 3 years of GRAZAX® treatment. Telephone interviews were conducted with patients to explore their experience of allergic rhinitis and AIT. Interview transcripts were analyzed using grounded theory methods. Saturation analysis was conducted for impact-related concepts. 3 allergists were also interviewed to explore their experience of treating allergic rhinitis. Results: 15 adults (aged 19-61) and 18 adolescents (aged 11-17) were interviewed. Clinicians and patients reported that before treatment with GRAZAX®, the most common allergic rhinitis symptoms were noseand eye-related. Together with coping strategies, these had considerable negative impacts on patients’ quality of life. Adults and adolescents reported notable improvement or disappearance of symptoms during treatment with GRAZAX®. Symptom reduction during treatment led to positive impacts on social, work/school, and physical functioning, with less need for impactful coping strategies. Some patients experienced oral side effects in the first months of AIT, though these resolved with time. Saturation of impact-related concepts was achieved. Conclusion: GRAZAX® treatment considerably improved allergic rhinitis symptoms and therefore impacted on daily life for patients during and after at least 3 years of treatment. Despite long recall periods, the consistency of reports between doctors, adolescents and adults, and achieving saturation suggest the robustness of the results; a three year course of treatment with GRAZAX® positively impacts quality of life and supports the existing clinical efficacy data on GRAZAX® treatment.
{"title":"The Burden of Allergic Rhinitis and Impact of GRAZAX® Grass Allergy Immunotherapy Treatment on Quality of Life in Germany and The Netherlands: Results from A Qualitative Study","authors":"N. Germain, R. V. Wijk, S. Aballéa, L. Abetz-Webb, A. Domdey, M. Romano, M. Toumi","doi":"10.23937/2572-3308.1510038","DOIUrl":"https://doi.org/10.23937/2572-3308.1510038","url":null,"abstract":"Background: Allergic rhinitis is a major chronic respiratory disease that affects between 10% and 30% of adults and up to 40% of children globally. The purpose of this study was to understand the impact of allergic rhinitis and subsequent GRAZAX® grass allergy immunotherapy (AIT) treatment on adults’ and adolescents’ quality of life. Methods: Clinicians treating allergic rhinitis in the Netherlands and Germany recruited adults and adolescents who had received at least 3 years of GRAZAX® treatment. Telephone interviews were conducted with patients to explore their experience of allergic rhinitis and AIT. Interview transcripts were analyzed using grounded theory methods. Saturation analysis was conducted for impact-related concepts. 3 allergists were also interviewed to explore their experience of treating allergic rhinitis. Results: 15 adults (aged 19-61) and 18 adolescents (aged 11-17) were interviewed. Clinicians and patients reported that before treatment with GRAZAX®, the most common allergic rhinitis symptoms were noseand eye-related. Together with coping strategies, these had considerable negative impacts on patients’ quality of life. Adults and adolescents reported notable improvement or disappearance of symptoms during treatment with GRAZAX®. Symptom reduction during treatment led to positive impacts on social, work/school, and physical functioning, with less need for impactful coping strategies. Some patients experienced oral side effects in the first months of AIT, though these resolved with time. Saturation of impact-related concepts was achieved. Conclusion: GRAZAX® treatment considerably improved allergic rhinitis symptoms and therefore impacted on daily life for patients during and after at least 3 years of treatment. Despite long recall periods, the consistency of reports between doctors, adolescents and adults, and achieving saturation suggest the robustness of the results; a three year course of treatment with GRAZAX® positively impacts quality of life and supports the existing clinical efficacy data on GRAZAX® treatment.","PeriodicalId":138186,"journal":{"name":"International Journal of Allergy Medications","volume":"68 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121949319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-12-31DOI: 10.23937/2572-3308.1510036
Baltazar Becerril-Bautista, Darío Jímenez-Uscanga Rubén, E. María, Alonso-Bello César Daniel, Fernando Lozano-Patiño, C. P. M. del, L. Juárez-Santiago, Castrejón-Vázquez María Isabel
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：